Pulmonary Vascular Remodeling Characteristics of Pulmonary Arterial Hypertension Mouse Model Induced by Left Pneumonectomy and Jugular Vein Injection of Monocrotaline Pyrrole

GU Li, LIU Cai-jun, XIE Liang, GU Ling, YU Li, LIU Han-min

Abstract

To compare and investigate the differences and characteristics of pulmonary vascular remodeling in three mouse models of pulmonary arterial hypertension (PAH) constructed by left pneumonectomy, jugular vein injection of monocrotaline pyrrole, and left pneumonectomy combined with jugular vein injection of monocrotaline pyrrole, to explore for a PAH animal model that approximates the clinical pathogenesis of PAH, and to create a model that will provide sound basis for thorough investigation into the pathogenesis of severe PAH.  Methods  59 male C57/BL mice (10-12 weeks, 24-30 g) were randomized into four groups, a control group (n=9), a group that had left pneumonectomy (PE, n=15), a group that had jugular vein injection of monocrotaline pyrrole (MCTP, n=15), and the last group that had left pneumonectomy combined with jugular injection of monocrotaline pyrrole (P+M, n=20). To evaluate the effect of modeling and the characteristics of pulmonary vascular remodeling, hemodynamic and morphological parameters, including right ventricular systolic pressure (RVSP), right ventricle/(left ventricle plus septum) (RV/LV+S), percent of wall thickness in the pulmonary artery (WT%), muscularization of non-muscular arteries, neointima formation, and vascular obstruction score (VOS), were measured in each group.   Results  1) Compared with those of the control group, the RVSP, RV/LV+S, WT%, and the degree of small pulmonary arteries muscularization in the P+M group were significantly increased (P<0.01). The MCTP group had just slightly higher findings for these indicators (P<0.05), while no significant change in these indicators was observed in the PE group (P>0.05). 2) Neointima formation in the acinus pulmonary arteries, which caused obvious stenosis of the lumen, was observed in the P+M group, the VOS being 1.25±0.80 points (P<0.001). In contrast, neointima formation was not observed in the MCTP group or the PE groups, the VOS being 0 point (P>0.05).  Conclusion  Left pneumonectomy combined with jugular intravenous injection of MCTP could induce severe PAH formation in mouse. The model provides a good simulation of neointima formation, the characteristic pathological change of clinical severe PAH.

 

Keywords: Pulmonary arterial hypertension, Pulmonary vascular remodeling, Animal model, Mouse

 

Full Text:

PDF


References


JIANG X， LI T， SUN J， et al. SETD3 negatively regulates VEGF expression during hypoxic pulmonary hypertension in rats. Hypertens Res，2018，41(9): 691–698.

BOURGEOIS A， LAMBERT C， HABBOUT K， et al. FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension. J Mol Med (Berl)，2018，96(2): 223–235.

OKADA K， TANAKA Y， BERNSTEIN M， et al. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol，1997，151(4): 1019–1025.

NISHIMURA T， FAUL J L， BERRY G J， et al. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med，2001，163(2): 498–502.

FAUL J L， NISHIMURA T， BERRY G J， et al. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med，2000，162(6): 2252–2258.

CHEN T， ZHOU G， ZHOU Q， et al. Loss of microRNA-17 approximately 92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. Am J Respir Crit Care Med，2015，191(6): 678–692.

GOTO J， ISHIKAWA K， KAWAMURA K， et al. Heme oxygenase-1 reduces murine monocrotaline-induced pulmonary inflammatory responses and resultant right ventricular overload. Antioxid Redox Signal，2002，4(4): 563–568.

QIAO L， NISHIMURA T， SHI L， et al. Endothelial fate mapping in mice with pulmonary hypertension. Circulation，2014，129(6): 692–703.

HOSHIKAWA Y， ONO S， SUZUKI S， et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol (1985)，2001，90(4): 1299–1306.

SCHERMULY R T， KREISSELMEIER K P， GHOFRANI H A， et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med，2004，169(1): 39–45.

NISHIMURA T， VASZAR L T， FAUL J L， et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation，2003，108(13): 1640–1645.

MONTANI D， JAÏS X， SITBON O， et al. Pulmonary arterial hypertension. Rev Mal Respir，2005，22(4): 651–666.

MEYRICK B. The pathology of pulmonary artery hypertension. Clin Chest Med，2001，22(3): 393–404.

PIETRA G G， CAPRON F， STEWART S， et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol，2004， 43(12 Suppl S): 25S–32S.

SMITH P， HEATH D. Electron microscopy of the plexiform lesion. Thorax，1979，34(2): 177–186.

SMITH P， HEATH D， YACOUB M， et al. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol，1990，160(2): 111–121.

PIETRA G G， EDWARDS W D， KAY J M， et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation，1989，80(5): 1198–1206.

DUFFELS M G， ENGELFRIET P M， BERGER R M， et al. Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry. Int J Cardiol，2007，120(2): 198–204. GOMEZ-ARROYO J G， FARKAS L， ALHUSSAINI A A， et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol，2012，302(4): L363–369.

KUANG T， WANG J， PANG B， et al. Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. Pulm Pharmacol Ther，2010，23(5): 456–464.

NISHIMURA T， FAUL J L， BERRY G J， et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med，2002，166(10): 1403–1408.

TANAKA Y， SCHUSTER D P， DAVIS E C， et al. The role of vascular injury and hemodynamics in rat pulmonary artery remodeling. J Clin Invest，1996，98(2): 434–442.

MITSUMATA M， FISHEL R S， NEREM R M， et al. Fluid shear stress stimulates platelet-derived growth factor expression in endothelial cells. Am J Physiol，1993，265(1 Pt 2): H3–H8.

HSIEH H J， LI N Q， FRANGOS J A. Shear-induced platelet-derived growth factor gene expression in human endothelial cells is mediated by protein kinase C. J Cell Physiol，1992，150(3): 552–558.

SUN H W， LI C J， CHEN H Q， et al. Involvement of integrins, MAPK, and NF-kappaB in regulation of the shear stress-induced MMP-9 expression in endothelial cells. Biochem Biophys Res Commun，2007， 353(1): 152–158.

BUDHIRAJA R， TUDER R M， HASSOUN P M. Endothelial dysfunction in pulmonary hypertension. Circulation，2004，109(2): 159–165.

FARBER H W， LOSCALZO J. Pulmonary arterial hypertension. N Engl J Med，2004，351(16): 1655–1665.


Refbacks

  • There are currently no refbacks.